February 22, 2022 Intelligence: Late-Breaking Lab News

Scopio Labs, a medical imaging company in Tel Aviv, recently landed $50 million in Series C venture capital funding as it moves to more fully enter the clinical laboratory market, TechCrunch reported on Feb. 9. Scopio has developed a scanner that can magnify a whole blood sample by 100 times. The digital imaging system provides clinicians with a view of all areas of the scan, including the peripheral edge. The company has raised a total of $85 million so far.

MORE ON: Scopio

One significant aspect of Scopio’s blood sampling technology it that it allows smear tests to be done remotely from any laptop, CEO Itai Hayut told TechCrunch. Other potential benefits of cell-imaging systems in general include reduced eyestrain for lab techs, lower labor costs, and easy archiving abilities, according to TechCrunch.


Labcorp bought the technology of Sterling, Va.-based Aperiomics in late 2021, according to the Washington Business Journal. The technology uses genomic sequencing and machine learning to identify pathogens.


Johan Hultin, MD, a pathologist who contributed to a breakthrough in the origins of the 1918 flu pandemic, died on Jan. 22 at age 97. In 1997, Hultin led a scientific trek to excavate a mass grave of 1918 flu victims near the Arctic Circle, according to the Washington Post. He removed a lung from a corpse and sent it to molecular pathologist Jeffery K. Taubenberger, MD, at the Armed Forces Institute of Pathology in Washington, DC. By 2005, Taubenberger’s team had deciphered the complete genome of the 1918 virus, the Post reported.


The Centers for Medicare and Medicaid Services (CMS) has delayed a planned revision to the Clinical Laboratory Improvement Amendments of 1988 (CLIA). In 2019, CMS published plans to update CLIA proficiency testing (PT) regulations to address current analytes and newer technologies. However, due to the COVID-19 pandemic, CMS has decided to release the updated PT requirements in 2023.


Genetic testing and technology company Centogene in Rostock, Germany, has named Kim Stratton as CEO. Stratton previously served as the company’s interim CEO. Prior to joining Centogene, she was CEO at biopharma company Orphazyme and Head of International Commercial for Shire Pharmaceutical’s rare disease business. 

That’s all the insider intelligence for this report. Look for the next briefing on Monday, March 14, 2022.




You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.